Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in ...
A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine ...
Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...
The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...
Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...
Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar ...
The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer ...
Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...
Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...
The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time ...
A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema ...
AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, Novo is shuttering its cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback